Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-controlled Trial
EBioMedicine, online 10 April 2018, https://doi.org/10.1016/j.ebiom.2018.04.010
Antonio J. Berlanga-Taylora, b, c, Katharine Plantb, Andrew Dahlb, Evelyn Laub, Michael Hilld, e, David Simsa, Andreas Hegera, Jonathan Embersond, e, Jane Armitaged, Robert Clarked, Julian C. Knightb,
- 291 genes improved expression by 2000 IU of vitamin D – RCT March 2013
Strangely, this key study was not in the references for the study on this page
- Genes and Vitamin D – literature review – Dec 2015
- Gene activation by high dose vitamin D - both quick and long term - April 2015
- Nanoemulsion Vitamin D may be a substantially better form
nano form had 3X increased activation of VDR gene
- Anti-inflamatory cytokines increased when vitamin D levels were raised above 30 ng – RCT Feb 2015
- We carried out molecular analyses in a randomized, double-blind, placebo-controlled, dose-finding clinical trial of daily vitamin D supplementation.
- Participants were Caucasian, aged over 65 years with measurements collected at baseline and 12 months for placebo, 2000 IU or 4000 IU, respectively.
- We did not find any significant differences in genomic, transcriptomic or selected cytokines in blood despite substantial changes in plasma 25(OH)D levels.
Many studies have reported associations of vitamin D deficiency with different diseases, but little is known about the causal relevance of such associations. Genomics technologies can provide important tools for discovery and validation of disease and drug mechanisms in clinical trials, but have not been widely used. Vitamin D is known to have genome-wide effects, but results have mainly come from laboratory models or small studies in humans.
Results of previous studies differ, possibly reflecting the complexity of synthesis and metabolism of vitamin D. In the present study, we used a randomized placebo-controlled trial, but did not observe any significant differences in expression in genes (genome-wide) or on plasma concentrations of selected cytokines in community-dwelling older individuals. Vitamin D is essential for human physiology and undoubtedly has multiple effects. Such effects are likely to vary between cells, tissues, individuals, populations and environmental circumstances. The mechanisms which regulate vitamin D are complex and likely to be robust to such differences. The present study shows that integrating high throughput molecular measurements is feasible in a community-based clinical trial and the results will inform future research investigating the mechanisms of action of vitamin D.
Vitamin D deficiency has been associated with multiple diseases, but the causal relevance and underlying processes are not fully understood. Elucidating the mechanisms of action of drug treatments in humans is challenging, but application of functional genomic approaches in randomized trials may afford an opportunity to systematically assess molecular responses.
In the Biochemical Efficacy and Safety Trial of Vitamin D (BEST-D), a double-blind, placebo-controlled, dose-finding, randomized clinical trial, 305 community-dwelling individuals aged over 65 years were randomly allocated to treatment with vitamin D3 4000 IU, 2000 IU or placebo daily for 12 months. Genome-wide genotypes at baseline, and transcriptome and plasma levels of cytokines (IFN-γ, IL-10, IL-8, IL-6 and TNF-α) at baseline and after 12 months, were measured. The trial had >90% power to detect 1.2-fold changes in gene expression.
Allocation to vitamin D for 12-months was associated with 2-fold higher plasma levels of 25-hydroxy-vitamin D (25OHD, 4000 IU regimen), but had no significant effect on whole-blood gene expression (FDR < 5%) or on plasma levels of cytokines compared with placebo. In pre-specified analysis, rs7041 (intron variant, GC) had a significant effect on circulating levels of 25(OH)D in the low dose, but not on the placebo or high dose vitamin D regimen. A gene expression quantitative trait locus analysis (eQTL) demonstrated evidence of 31,568 cis-eQTLs (unique SNP-probe pairs) among individuals at baseline and 34,254 after supplementation for 12 months (any dose). No significant associations involving vitamin D supplementation response eQTLs were found.
We performed a comprehensive functional genomics and molecular analysis of vitamin D supplementation in a randomized, placebo-controlled trial. Although this study was limited to mostly Caucasian individuals aged over 65 years, the results differ from many previous studies and do not support a strong effect of vitamin D on long-term transcriptomic changes in blood or on plasma cytokine levels. The trial demonstrates the feasibility of applying functional genomic and genetic approaches in randomized trials to assess molecular and individual level responses.
Supplementation with high-dose vitamin D in older people for 12 months in a randomized, placebo-controlled trial had no significant effect on gene expression or on plasma concentrations of selected cytokines.
SRCTN registry (Number 07034656) and the European Clinical Trials Database (EudraCT Number 2011-005763-24).